HHS Opens Door for Compounding Pharmacies to Make Popular Peptides

Birmingham, Ala. The Department of Health and Human Services announced Tuesday that it will exercise enforcement discretion for six popular peptides, allowing small compounding pharmacies to manufacture and sell the compounds. The policy shifts the regulatory stance on substances that have long circulated in the gray market despite a formal ban on their production by these specific facilities.

Health Secretary Robert F. Kennedy Jr., a vocal proponent of peptide use, stated that the administration is moving to bring these products out of the shadows. The six peptides covered by the new policy are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Proponents have promoted these amino acid strings for conditions ranging from insomnia and migraines to wound healing and metabolic health, though clinical evidence for their safety and effectiveness remains sparse.

The policy specifically targets 503A compounding pharmacies, which are smaller facilities that prepare medications for specific patients. It does not apply to 503B outsourcing facilities, which produce higher volumes of medicine. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said his company has received years of customer inquiries but could not legally compound the peptides before this change. Under the new rules, only his smaller facility can make them, and only in limited quantities.

Fritzler warned that supply will remain tight. “We won’t be able to meet demand,” he said, noting that Olympia will likely compound only one of the six peptides initially. He added, “I don’t think all the [503]As in the country could meet the demand.” Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said the decision offers a “more accountable alternative” to illicit online suppliers. He noted that the move brings patients into a system with pharmacy standards and adverse event reporting.

Critics argue the decision bypasses standard regulatory procedures. In July, an FDA advisory panel voted to support expanded access to the peptides, but FDA scientists at the same meeting recommended against unwinding existing restrictions. Dr. Robert Steinbrook, health research group director at Public Citizen, wrote that Kennedy acted unilaterally rather than through typical rulemaking. “Kennedy has undermined the FDA and threatened public health,” Steinbrook stated. He advised clinicians to inform patients about contamination risks.

Shabbir Safda, executive director of the Partnership for Safe Medicines, filed a citizen petition last week urging the FDA to ignore the advisory committee’s July recommendation. “Today’s decision leaves Americans in a grey area as to whether peptides are safe or not,” Safda wrote. He cited the FDA scientists’ concerns regarding the lack of evidence. Brunner cautioned that it may take time for pharmacies to begin dispensing the products, as suppliers and pharmacies must verify that active ingredients meet the policy’s requirements.

The new policy describes compounding as a safer alternative to “research-use-only” peptides often sourced from overseas suppliers. The administration’s move allows these unproven compounds to be manufactured and prescribed without immediate threat of federal enforcement actions, creating a new path for patients seeking treatments that have not completed the FDA’s rigorous drug approval process.